ResMed heart attack trial stopped after putting patients at risk, page-35

magicwand, you clearly don't understand.
Obstructive sleep apnoea is an enormous and growing health problem which is where Resmed's CPAP masks have been growing profits year in year out and will continue to do so.
This trial relates to Resmed hoping to expand their product onto heart failure patients, but clearly is a failure. It won't mean the failure of their core business which should continue to grow. If you think CPAP is "bottled air" then you clearly have no understanding of medical issues. I suggest you speak to a medical professional about the massive health problem that is obstructive sleep apnoea.
Having said that, I sold at $8.10 ( nice profit ) as I thought the PE ratio was getting astronomically high for this stock. From charting perspective it would be a great pick up in the high 5's.